NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

• Main Authors: Helene Cawston (Author), Francois Bourhis (Author), Jennifer Eriksson (Author), Pierfrancesco Ruffo (Author), Paolo D'Agostino (Author), Marco Turini (Author), Lee Schwartzberg (Author), Alistair McGuire (Author)
• Format: Book
• Published: BioExcel Publishing Ltd, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...